Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics Inc. produced more positive interim data from early stage studies of its gene therapy to treat Friedreich’s ataxia cardiomyopathy. The results have prompted the company to continue ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

A West Annapolis family has turned two life-altering diagnoses into more than $1 million for research toward finding a cure ...

Lexeo Therapeutics, Inc, a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced positive interim data across all dose cohorts of ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human ...

"Late onset FA is a strange mix of feeling sad about the diagnosis and worrying about the future, and feeling happy that I ...

Discover how neuroimaging uncovers Friedreich ataxia progression patterns. Learn how biomarkers could transform clinical ...